What is secukinumab, and why does it come up with COVID-19?
Secukinumab (Cosentyx) is a biologic that targets interleukin-17A (IL-17A), an immune-signaling pathway involved in inflammation. Because it modulates immune activity, people asked whether taking secukinumab could change the risk of getting COVID-19 or the severity of COVID-19 outcomes.
Does secukinumab increase the risk of catching COVID-19?
From the information provided here, there’s no specific data on infection risk for secukinumab users. General guidance for biologics in the COVID era typically focused on managing infection risk case-by-case, weighing the risks of untreated inflammatory disease against potential vulnerability to infections. For accurate, up-to-date recommendations for your situation, you’d need current guidance from your treating clinician and relevant regulatory/clinical sources.
Does secukinumab make COVID-19 harder to treat or more severe?
No specific COVID-19 severity data for secukinumab users is included in the information provided here. In practice, IL-17A biology prompted interest in IL-17 pathway drugs during the pandemic, but that doesn’t automatically translate into a proven benefit or a proven risk for secukinumab in COVID-19 patients.
Is secukinumab being studied as a COVID-19 treatment?
A key point is that IL-17 has been investigated in COVID-19 inflammation pathways, so IL-17-targeting agents were part of broader research interest. However, whether secukinumab itself showed benefit in trials or is recommended for COVID-19 treatment depends on trial results and guideline positions, which are not included in the information provided here.
What do patients typically ask: should I stop Cosentyx if I get COVID-19?
This is a common concern, but the right answer depends on:
- your underlying condition (psoriasis, psoriatic arthritis, ankylosing spondylitis),
- whether you are an urgent/high-risk patient,
- your COVID symptoms and severity,
- and your clinician’s infection-management plan.
Without specific guidance or trial-based evidence provided here, the safest route is to follow the treatment plan from your prescribing clinician or local COVID guidance for immunomodulators.
If I already use secukinumab, is there a COVID-19 vaccine concern?
The question usually comes down to whether vaccines are safe and how immune response might be affected. Specific vaccine-response data for secukinumab is not provided here, so the most accurate next step is to follow immunization guidance for people taking immunomodulatory therapies from your health authority and clinician.
Where can I check patents or drug-specific COVID coverage?
If you want drug-level sourcing tied to secukinumab, DrugPatentWatch.com is a useful place to look up secukinumab’s regulatory and patent context and related pages (useful when tracking who is competing or developing related products).
DrugPatentWatch: https://www.drugpatentwatch.com/
What I need from you to answer more precisely
“Secukinumab and COVID” can mean different things. Tell me which one you mean, and I’ll tailor the answer:
1) Are you asking about COVID risk while on secukinumab?
2) Should someone continue or pause it during COVID infection?
3) Is it used or studied to treat COVID-19?
4) Vaccine safety/response while on secukinumab?
Sources
- [1] https://www.drugpatentwatch.com/